Edition:
United Kingdom

PTC Therapeutics Inc (PTCT.OQ)

PTCT.OQ on NASDAQ Stock Exchange Global Select Market

36.01USD
22 Jun 2018
Change (% chg)

$-0.30 (-0.83%)
Prev Close
$36.31
Open
$36.42
Day's High
$36.69
Day's Low
$34.97
Volume
949,658
Avg. Vol
387,262
52-wk High
$52.95
52-wk Low
$14.57

Latest Key Developments (Source: Significant Developments)

D. E. Shaw & Co Reports 5 Pct Passive Stake In PTC Therapeutics
Tuesday, 29 May 2018 

May 29 (Reuters) - PTC Therapeutics Inc ::D. E. SHAW & CO., L.P REPORTS A 5.0 PERCENT PASSIVE STAKE IN PTC THERAPEUTICS AS OF MAY 16, 2018 - SEC FILING.  Full Article

PTC Therapeutics Prices Public Offering Of Common Stock At $27.04 Per Share​
Thursday, 29 Mar 2018 

March 28 (Reuters) - Ptc Therapeutics Inc ::PTC THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.‍PRICING OF A PUBLIC OFFERING OF 4,000,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $27.04 PER SHARE​.  Full Article

PTC Therapeutics reports qtrly net loss per share basic and diluted of $0.82
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Ptc Therapeutics Inc ::Qtrly total revenues $41.9 million versus $22.98 million.Qtrly net loss per share basic and diluted $0.82.Q3 earnings per share view $-0.68, revenue view $42.2 million -- Thomson Reuters I/B/E/S.Increasing 2017 revenue guidance to $160-$185M​.FY2017 revenue view $173.4 million -- Thomson Reuters I/B/E/S.  Full Article

Camber Capital Management LLC reports 5.84 pct passive stake in PTC Therapeutics
Thursday, 29 Sep 2016 

Camber Capital Management LLC:Camber Capital Management LLC reports 5.84 pct passive stake in PTC Therapeutics Inc as of Sept. 19 - SEC filing.  Full Article

PTC Therapeutics qtrly Translarna net sales of $15.4 mln
Thursday, 4 Aug 2016 

PTC Therapeutics Inc : Says full-year Translarna net sales on-track to meet guidance of $65m to $85m . Says ema review of european marketing authorization for translarna continues .Qtrly Translarna net sales of $15.4m.  Full Article

PTC Therapeutics provides regulatory update on Translarna
Monday, 25 Jul 2016 

: Says no longer anticipates that chmp will issue its opinion regarding ema approval of translarna in mid-2016 . Says confirmatory phase 3 act cf trial of translarna is currently ongoing . Says there is substantial risk that results from translarna trial, expected in early 2017, will be required for approval . Ptc therapeutics provides regulatory update on translarna™ (ataluren) . Ptc Therapeutics Inc Says Company Has Been Informed That Renewal Assessment Procedure Cannot Be Completed By Mid Year 2016 . Expects translarna's current marketing authorization status will remain valid until a decision is adopted by european commission .Chmp has agreed to proposal by ptc to submit a draft clinical trial protocol for translarna for further discussion.  Full Article

PTC Therapeutics and NHS England negotiate managed access agreement
Thursday, 7 Jul 2016 

PTC Therapeutics Inc : Co and NHS England negotiate managed access agreement translarna for patients with nonsense mutation duchenne muscular dystrophy .Decision provides reimbursed patient access to translarna in england via a five-year MAA.  Full Article

Roche SMA drug shines in study as costly new therapies advance

ZURICH, June 18 A drug being co-developed by Roche to treat spinal muscular atrophy (SMA) helped improve development scores in babies with the genetic disease, a study released on Monday showed, as the race heats up for therapies destined to be among the drug industry's most expensive.